Novel Bioventures is a venture capital fund focused on early stage investments.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
May 11, 2005
Cellerant Therapeutics
|
Series B | $16M | Biotechnology | Yes |
Jan 27, 2005
Predix Pharmaceuticals
|
Series C | $43M | Health Care | — |
Jun 1, 2004
ARYx Therapeutics
|
Series D | $55M | Biotechnology | — |
Jan 27, 2004
TransMedics
|
Series B | $27.60M | Health Care | — |
Novel Bioventures has had 3 exits. Novel Bioventures most notable exits include TransMedics , ARYx Therapeutics
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
May 1, 2019 | TransMedics | IPO | Health Care | Detail |
Nov 7, 2007 | ARYx Therapeutics | IPO | Biotechnology | Detail |
Oct 26, 2005 | Predix Pharmaceuticals | M&A | Health Care | Detail |